Loading...
Loading...
BFRI| Name | Value |
|---|---|
| Revenues | 8,733.0K |
| Cost of Revenue | 4,598.0K |
| Gross Profit | 4,135.0K |
| Operating Expense | 9,827.0K |
| Operating I/L | -5,692.0K |
| Other Income/Expense | -1,981.0K |
| Interest Income | 56.0K |
| Pretax | -7,473.0K |
| Income Tax Expense | 5.0K |
| Net Income/Loss | -7,478.0K |
Biofrontera Inc. is a biopharmaceutical company specializing in the commercialization of pharmaceutical products for dermatological conditions in the United States. Its flagship product, Ameluz, is a prescription drug used in combination with the RhodoLED lamp series for photodynamic therapy to treat actinic keratosis. Additionally, the company offers Xepi, a prescription cream for impetigo treatment. Biofrontera generates revenue through the sale of these prescription drugs and medical devices, catering to the needs of patients with dermatological conditions.
